These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 39092594)
1. Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy. Ji P; Yang L; Zhu L; Hu L; Wang Y; Shi C; Jiang Q; Huang N; Yang Y; Chen H; Zhu R Pediatr Allergy Immunol; 2024 Aug; 35(8):e14207. PubMed ID: 39092594 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis]. Huang HH; Xu C; Liu L; Chai RN Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859 [No Abstract] [Full Text] [Related]
3. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases. Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756 [TBL] [Abstract][Full Text] [Related]
5. Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling. Xie S; Fan R; Tang Q; Cai X; Zhang H; Wang F; Xie S; Gao K; Zhang J; Xie Z; Jiang W Front Immunol; 2021; 12():805404. PubMed ID: 35095890 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762 [TBL] [Abstract][Full Text] [Related]
7. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501 [TBL] [Abstract][Full Text] [Related]
8. Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis. Huang J; Xiang R; Tan L; Deng Y; Tao Z; Zhang W; Xu Y Int Immunopharmacol; 2023 Dec; 125(Pt A):111111. PubMed ID: 37925948 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study. Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838 [TBL] [Abstract][Full Text] [Related]
10. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis. Wang ZX; Shi H J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143 [TBL] [Abstract][Full Text] [Related]
11. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis. Wang N; Song J; Sun SR; Zhu KZ; Li JX; Wang ZC; Guo CL; Xiang WX; Tong YL; Zeng M; Wang H; Xu XY; Yao Y; Liu Z Allergy; 2024 May; 79(5):1230-1241. PubMed ID: 38403941 [TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188 [TBL] [Abstract][Full Text] [Related]
13. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects. Chaoul N; Albanesi M; Giliberti L; Rossi MP; Nettis E; Di Bona D; Caiaffa MF; Macchia L Int Arch Allergy Immunol; 2019; 179(1):37-42. PubMed ID: 30921804 [TBL] [Abstract][Full Text] [Related]
14. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study. Hamada M; Saeki K; Tanaka I Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306 [TBL] [Abstract][Full Text] [Related]
15. [Observation and analysis of systemic reactions to house dust mite subcutaneous immunotherapy in 362 patients with allergic rhinitis]. Xue JR; Ma J; Qiu CY; Hu ZB; Jiang X; Pan M; Lu MP; Cheng L Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 May; 55(5):445-451. PubMed ID: 32842357 [No Abstract] [Full Text] [Related]
16. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Blumberga G; Groes L; Dahl R Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456 [TBL] [Abstract][Full Text] [Related]
17. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Calderon MA; Casale TB; Nelson HS; Demoly P J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors. Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269 [TBL] [Abstract][Full Text] [Related]
19. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma. Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351 [TBL] [Abstract][Full Text] [Related]
20. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. Richards JR; Stumpf JL Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]